The estimated Net Worth of Barry D Michaels is at least $3.21 Milion dollars as of 29 December 2014. Mr. Michaels owns over 15,000 units of Zynex Inc stock worth over $2,273,742 and over the last 13 years he sold ZYXI stock worth over $886,652. In addition, he makes $50,000 as Independent Director at Zynex Inc.
Barry has made over 7 trades of the Zynex Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 15,000 units of ZYXI stock worth $112,500 on 29 December 2014.
The largest trade he's ever made was selling 85,353 units of Zynex Inc stock on 16 December 2013 worth over $774,152. On average, Barry trades about 9,926 units every 48 days since 2012. As of 29 December 2014 he still owns at least 285,646 units of Zynex Inc stock.
You can see the complete history of Mr. Michaels stock trades at the bottom of the page.
Barry D. Michaels serves as Independent Director of the Company. Mr. Michaels has more than 35 years of financial and general management experience in the medical device and biotechnology industries with industry leaders including Medtronic, Johnson and Johnson, and Baxter Healthcare. Mr. Michaels served as Chief Financial Officer of three private and four publicly traded companies including Cardima, Inc., Lipid Sciences, Inc., ICN Biomedicals, Inc., IntraTherapeutics, Inc., VIA Medical, and Webster Laboratories. In addition, he served as President of a Johnson and Johnson division and acting Chief Executive Officer of Lipid Sciences, Inc. He has raised nearly $800 million in capital within public and private market environments, has taken two companies public, and has led three private companies to favorable liquidity events. He has also served as an independent consultant to medical device and biotechnology companies since 1997 leveraging his strong mix of organizational, operational, and financial management skills to advise senior management and directors. During his tenure in executive management Mr. Michaels added over 1,100 jobs to the economy and increased shareholder value by more than $2 billion. Mr. Michaels holds a BA in Audiology and an MBA in Finance from San Diego State University and is a graduate of the Executive Program at the University of California, Los Angeles. In addition, he has completed the UCLA Director’s Education Program certification exam and has served as Corporate Secretary to three publicly traded companies.
As the Independent Director of Zynex Inc, the total compensation of Barry Michaels at Zynex Inc is $50,000. There are 6 executives at Zynex Inc getting paid more, with Giuseppe Papandrea having the highest compensation of $1,901,890.
Barry Michaels is 70, he's been the Independent Director of Zynex Inc since 2018. There are no older and 8 younger executives at Zynex Inc.
Barry's mailing address filed with the SEC is 9655 MAROON CIRCLE, , ENGLEWOOD, CO, 80112.
Over the last 6 years, insiders at Zynex Inc have traded over $45,302,249 worth of Zynex Inc stock and bought 14,733 units worth $121,235 . The most active insiders traders include Thomas Sandgaard Holdings L..., Joshua R. Disbrow oraz Thomas Sandgaard. On average, Zynex Inc executives and independent directors trade stock every 56 days with the average trade being worth of $657,783. The most recent stock trade was executed by Anna Lucsok on 6 August 2024, trading 24,875 units of ZYXI stock currently worth $199,498.
zynex, inc. founded in 1996, engineers, manufactures and markets neuro-diagnostics, stroke rehabilitation, pain management and cardiac monitoring devices within three subsidiaries. zynex medical is a provider of electrotherapy products for home use. zynex monitoring solutions develops products for cardiac monitoring for use in hospitals. zynex neurodiagnostics develops devices for emg and eeg diagnostic applications within neurology disciplines. zynex medical's product line is fully developed, fda/ce cleared, commercially sold, and has been developed to uphold the company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. zynex monitoring solutions and zynex neurodiagnostics are currently both in the development stages without any significant revenues.
Zynex Inc executives and other stock owners filed with the SEC include: